Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-015536
Filing Date
2022-08-08
Accepted
2022-08-08 16:14:22
Documents
67
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q atra-20220630.htm   iXBRL 10-Q 3228111
2 EX-10.1 atra-ex10_1.htm EX-10.1 25675
3 EX-31.1 atra-ex31_1.htm EX-31.1 17431
4 EX-31.2 atra-ex31_2.htm EX-31.2 17314
5 EX-32.1 atra-ex32_1.htm EX-32.1 12817
  Complete submission text file 0000950170-22-015536.txt   10415664

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT atra-20220630.xsd EX-101.SCH 64254
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT atra-20220630_def.xml EX-101.DEF 166212
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT atra-20220630_pre.xml EX-101.PRE 328333
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT atra-20220630_cal.xml EX-101.CAL 63756
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT atra-20220630_lab.xml EX-101.LAB 484708
61 EXTRACTED XBRL INSTANCE DOCUMENT atra-20220630_htm.xml XML 2035662
Mailing Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-278-8930
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

EIN.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36548 | Film No.: 221144543
SIC: 2836 Biological Products, (No Diagnostic Substances)